Paul Tudor Jones’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15M | Buy |
+30,176
| New | +$13.4M | 0.02% | 616 |
|
|
2026
Q1 | – | Sell |
-5,641
| Closed | -$2.63M | – | 4340 |
|
|
2025
Q4 | $2.56M | Sell |
5,641
-45,733
| -89% | -$19.7M | ﹤0.01% | 1629 |
|
|
2025
Q3 | $20.1M | Buy |
+51,374
| New | +$21.5M | 0.03% | 431 |
|
|
2025
Q1 | – | Sell |
-9,463
| Closed | -$3.81M | – | 3730 |
|
|
2024
Q4 | $3.81M | Buy |
+9,463
| New | +$4.39M | 0.01% | 845 |
|
|
2024
Q2 | – | Sell |
-23,529
| Closed | -$9.84M | – | 2841 |
|
|
2024
Q1 | $9.84M | Sell |
23,529
-2,876
| -11% | -$1.22M | 0.06% | 359 |
|
|
2023
Q4 | $10.7M | Sell |
26,405
-6,950
| -21% | -$2.57M | 0.09% | 322 |
|
|
2023
Q3 | $11.6M | Buy |
+33,355
| New | +$11.7M | 0.12% | 178 |
|
|
2023
Q1 | – | Sell |
-7,580
| Closed | -$2.19M | – | 2994 |
|
|
2022
Q4 | $2.19M | Buy |
+7,580
| New | +$2.31M | 0.04% | 587 |
|
|
2021
Q4 | – | Sell |
-29,658
| Closed | -$5.38M | – | 3070 |
|
|
2021
Q3 | $5.38M | Buy |
+29,658
| New | +$5.79M | 0.09% | 244 |
|
|
2021
Q2 | – | Sell |
-17,262
| Closed | -$3.71M | – | 1970 |
|
|
2021
Q1 | $3.71M | Sell |
17,262
-29,041
| -63% | -$6.38M | 0.07% | 276 |
|
|
2020
Q4 | $10.9M | Buy |
46,303
+40,600
| +712% | +$9.32M | 0.31% | 40 |
|
|
2020
Q3 | $1.55M | Sell |
5,703
-2,084
| -27% | -$575K | 0.07% | 393 |
|
|
2020
Q2 | $2.26M | Sell |
7,787
-2,585
| -25% | -$701K | 0.11% | 208 |
|
|
2020
Q1 | $2.47M | Sell |
10,372
-5,276
| -34% | -$1.21M | 0.22% | 65 |
|
|
2019
Q4 | $3.43M | Buy |
+15,648
| New | +$3.17M | 0.15% | 150 |
|
|
2019
Q1 | – | Sell |
-6,359
| Closed | -$1.05M | – | 1292 |
|
|
2018
Q4 | $1.05M | Sell |
6,359
-1,943
| -23% | -$337K | 0.02% | 370 |
|
|
2018
Q3 | $1.6M | Sell |
8,302
-9,286
| -53% | -$1.65M | 0.04% | 336 |
|
|
2018
Q2 | $2.99M | Buy |
17,588
+15,157
| +623% | +$2.35M | 0.1% | 166 |
|
|
2018
Q1 | $396K | Sell |
2,431
-7,985
| -77% | -$1.3M | 0.01% | 644 |
|
|
2017
Q4 | $1.56M | Buy |
+10,416
| New | +$1.54M | 0.04% | 233 |
|
|
2017
Q1 | – | Sell |
-9,611
| Closed | -$708K | – | 1571 |
|
|
2016
Q4 | $708K | Buy |
+9,611
| New | +$782K | 0.02% | 536 |
|
|
2016
Q1 | – | Sell |
-6,286
| Closed | -$791K | – | 1991 |
|
|
2015
Q4 | $791K | Buy |
+6,286
| New | +$759K | 0.02% | 586 |
|
|
2015
Q3 | – | Sell |
-2,729
| Closed | -$337K | – | 1774 |
|
|
2015
Q2 | $337K | Buy |
+2,729
| New | +$344K | 0.01% | 1041 |
|
|
2015
Q1 | – | Sell |
-6,589
| Closed | -$783K | – | 1630 |
|
|
2014
Q4 | $783K | Sell |
6,589
-1,137
| -15% | -$128K | 0.03% | 479 |
|
|
2014
Q3 | $868K | Buy |
7,726
+5,548
| +255% | +$528K | 0.03% | 363 |
|
|
2014
Q2 | $206K | Buy |
+2,178
| New | +$153K | 0.01% | 1034 |
|
Other funds holding VRTX
Paul Tudor Jones's VRTX Position: Q2 2026 in Review
Paul Tudor Jones opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 30,176 shares worth $15M. The stake represents 0.02% of the portfolio and ranks #616 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in VRTX as recently as Q4 2025.
Paul Tudor Jones first reported a position in VRTX in Q2 2014 and has held it in 26 quarters since. The position peaked at $20.1M in Q3 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Paul Tudor Jones held 30,176 shares of Vertex Pharmaceuticals worth $15M as of Q2 2026.
- Vertex Pharmaceuticals was a new Paul Tudor Jones position in Q2 2026.
- Vertex Pharmaceuticals made up 0.02% of Paul Tudor Jones's portfolio in Q2 2026, its #616 holding.
- Paul Tudor Jones first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
- Paul Tudor Jones's Vertex Pharmaceuticals position peaked at $20.1M in Q3 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.